G
Guillaume Bouguen
Researcher at University of Rennes
Publications - 193
Citations - 5507
Guillaume Bouguen is an academic researcher from University of Rennes. The author has contributed to research in topics: Inflammatory bowel disease & Medicine. The author has an hindex of 31, co-authored 155 publications receiving 4187 citations. Previous affiliations of Guillaume Bouguen include French Institute of Health and Medical Research & University of California, San Diego.
Papers
More filters
Journal ArticleDOI
Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.
Laurent Peyrin-Biroulet,William J. Sandborn,Bruce E. Sands,Walter Reinisch,Walter Reinisch,Willem A. Bemelman,Robert V Bryant,G R D’Haens,Iris Dotan,Marla Dubinsky,Brian G. Feagan,Gionata Fiorino,Richard B. Gearry,S. Krishnareddy,Peter L. Lakatos,Edward V. Loftus,P. Marteau,Pia Munkholm,Travis B. Murdoch,Ingrid Ordás,Remo Panaccione,Robert H. Riddell,J. Ruel,David T. Rubin,Mark A Samaan,Corey A. Siegel,Mark S. Silverberg,Jaap Stoker,Stefan Schreiber,Simon Travis,G. Van Assche,G. Van Assche,Silvio Danese,Julián Panés,Guillaume Bouguen,Sarah O’Donnell,Benjamin Pariente,S. Winer,Stephen B. Hanauer,J.-F. Colombel +39 more
TL;DR: Evidence- and consensus-based recommendations for selecting the goals for treat-to-target strategies in patients with IBD are made available and future studies are needed to determine how these targets will change disease course and patients’ quality of life.
Journal ArticleDOI
Treat to target: a proposed new paradigm for the management of Crohn's disease.
Guillaume Bouguen,Barrett G. Levesque,Brian G. Feagan,Arthur Kavanaugh,Laurent Peyrin-Biroulet,Jean-Frederic Colombel,Stephen B. Hanauer,William J. Sandborn +7 more
TL;DR: A "treat to target" strategy that is based on regular assessment of disease activity by using objective clinical and biological outcome measures and the subsequent adjustment of treatments and is complementary to the concept of early intervention in high-risk patients is proposed.
Journal ArticleDOI
Surgery for adult Crohn's disease: what is the actual risk?
TL;DR: The aim of this article is to review the risk of surgery before and in the era of biologics and to discuss the impact of medications on this risk, with a focus on adult luminal CD.
Journal ArticleDOI
Efficacy of adalimumab in patients with Crohn's disease and symptomatic small bowel stricture: a multicentre, prospective, observational cohort (CREOLE) study.
Yoram Bouhnik,Franck Carbonnel,David Laharie,Carmen Stefanescu,Xavier Hébuterne,Vered Abitbol,Maria Nachury,Hedia Brixi,Arnaud Bourreille,Laurence Picon,Anne Bourrier,Matthieu Allez,Laurent Peyrin-Biroulet,Jacques Moreau,Guillaume Savoye,Mathurin Fumery,Stéphane Nancey,Xavier Roblin,Romain Altwegg,Guillaume Bouguen,Gilles Bommelaer,Silvio Danese,Edouard Louis,Magaly Zappa,Jean-Yves Mary +24 more
TL;DR: A successful response to adalimumab was observed in about two-thirds of CD patients with SSBS and was prolonged in nearly half of them till the end of follow-up, and more than half of the patients were free of surgery 4 years after treatment initiation.
Journal ArticleDOI
Long-term outcome of perianal fistulizing Crohn's disease treated with infliximab
Guillaume Bouguen,Laurent Siproudhis,Emmanuel Gizard,Timothée Wallenhorst,Vincent Billioud,Jean François Bretagne,Marc André Bigard,Laurent Peyrin Biroulet +7 more
TL;DR: Combination therapy, duration of seton drainage less than 34 weeks, and long-term treatment with infliximab were associated with better outcomes, and about two-thirds of patients with fistulizing perianal Crohn's disease had fistula closure, and one-third had fistulas recurrence after inflixIMab initiation.